Cisplatin, vinblastine, and mitoguazone in squamous cell carcinoma of the esophagus: a Southwest Oncology Group Study.
Forty patients with locally extensive or metastatic squamous cell carcinoma of the esophagus were registered onto a phase II trial employing cisplatin, vinblastine, and mitoguazone. Of 36 eligible patients, four (11%) had partial responses. None had received prior chemotherapy or radiation therapy. Toxicity was mild to moderate and consisted mostly of nausea and vomiting. The activity of this regimen at the doses and schedule used was minimal. More aggressive use of therapy should be considered for further trials.
Chapman
R
R
Henry Ford Hospital, Detroit, MI.
Fleming
T R
TR
Van Damme
J
J
Macdonald
J
J
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008935:Mitoguazone / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D008935:Mitoguazone; D002945:Cisplatin